TURKISH JOURNAL OF MEDICAL SCIENCES, vol.47, no.4, pp.1247-1256, 2017 (SCI-Expanded)
Background/aim: Immunogenicity and safety of a primary series of a fully liquid, hexavalent DTaP-IPV-HB-PRP-T vaccine given at 2, 3, and 4 months of age compared to licensed comparators and a DTaP-IPV-HB-PRP-T booster at 15-18 months were evaluated.